WuXi AppTec disclosed a cybersecurity incident involving unauthorized access to its DNA-encoded library platform, sending shares down 3.9%. The company contained the breach to the DEL system and confirmed normal operations continued.
Retour
WuXi AppTec drops 3.9% after cyber breach hits DEL platform
WuXi AppTec shares dropped 3.9% after the Hong Kong-listed contract research firm disclosed unauthorized access to its DNA-encoded library platform used in drug discovery.
The company said it activated its emergency response mechanism, engaged external cybersecurity experts and legal advisers, and contained the breach to the DEL system with no evidence of impact on other systems. The most recent analyst rating on the stock is a Buy with a HK$210.00 price target.
Shares fell HK$8.10 to close down 3.936%, with short selling reaching HK$357.54 million at a 24.602% ratio. The company's market capitalization stands at HK$562.1 billion, with average daily trading volume of 7.1 million shares.
The incident raises questions about data security at one of the world's largest contract research organizations, which handles proprietary research data for global pharmaceutical and biotech clients. WuXi AppTec said it is strengthening system protections and has notified affected biology customers whose data files were compromised.
The company emphasized that the incident has not disrupted normal operations, with all IT systems including the DEL platform functioning normally. Management urged shareholders and potential investors to exercise caution when trading its shares while the company reviews the incident's implications.
The DEL platform is a professional encoded chemical synthesis library used for early-stage discovery projects. WuXi AppTec's Biology segment operates digital platforms and data-intensive services that are integral to customers' research workflows. The company serves a broad base of international stakeholders who rely on secure handling of proprietary research data and uninterrupted operational support for discovery projects. WuXi AppTec is a China-based contract research and development organization focused on providing biology and chemistry services to global pharmaceutical and biotech clients, with offerings including specialized platforms such as DNA-encoded libraries used for early-stage discovery of new chemical compounds.
The cybersecurity incident could affect new business acquisition and renewals in the biology segment if clients question the company's ability to protect proprietary research data. Data security and intellectual property protection are critical in the CRO/CDMO industry, where pharmaceutical companies entrust contract partners with sensitive compound libraries and research findings. WuXi AppTec is working with experts to complete the investigation and has added additional security protocols.
The stock's decline comes as the broader Hong Kong market faces pressure from global trade uncertainty. WuXi AppTec's technical sentiment signal remains a Buy, according to TipRanks data, though the incident's full implications for the company's biology business are still under review. The company's next key event will be the completion of its investigation and any disclosures about the scope of data exposure.
This article is for informational purposes only and does not constitute investment advice.
Fonctionnalités
© 2026 Edgen fonctionné par